Edwards Lifesciences Corporation (4EW.TI)
| Previous Close | 83.90 |
| Open | 87.38 |
| Bid | 85.74 x N/A |
| Ask | 86.03 x N/A |
| Day's Range | 79.87 - 87.38 |
| 52 Week Range | 57.94 - 88.14 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 24, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Investors in Edwards Lifesciences (NYSE:EW) have seen favorable returns of 42% over the past five years
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...
ZacksBD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.
Business WireFive-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus size or sex. These data were presented during the late-breaking clinical
